262 related articles for article (PubMed ID: 35020530)
1. Systematic review of the efficacy, effectiveness and impact of high-valency pneumococcal conjugate vaccines on otitis media.
Izurieta P; Scherbakov M; Nieto Guevara J; Vetter V; Soumahoro L
Hum Vaccin Immunother; 2022 Dec; 18(1):2013693. PubMed ID: 35020530
[TBL] [Abstract][Full Text] [Related]
2. Impact of pneumococcal conjugate vaccines on healthcare utilization and direct costs for otitis media in children ≤2 years of age in two Swedish regions.
Edmondson-Jones M; Dibbern T; Hultberg M; Anell B; Medin E; Feng Y; Talarico C
Hum Vaccin Immunother; 2022 Dec; 18(1):1942712. PubMed ID: 34319865
[TBL] [Abstract][Full Text] [Related]
3. Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease.
Izurieta P; Nieto Guevara J
Hum Vaccin Immunother; 2022 Dec; 18(1):1872341. PubMed ID: 33605846
[TBL] [Abstract][Full Text] [Related]
4. The effect of pneumococcal conjugate vaccines on otitis media from 2005 to 2013 in children aged ≤5 years: a retrospective cohort study in two Swedish regions.
Edmondson-Jones M; Dibbern T; Hultberg M; Anell B; Medin E; Feng Y; Talarico C
Hum Vaccin Immunother; 2021 Feb; 17(2):517-526. PubMed ID: 32574101
[TBL] [Abstract][Full Text] [Related]
5. A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia.
Lagoubi Y; Sfar MT; Gomez JA
Hum Vaccin Immunother; 2022 Nov; 18(5):2079305. PubMed ID: 35703731
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Comparison of Pneumococcal Conjugate Vaccines in Turkish Children.
Marijam A; Olbrecht J; Ozakay A; Eken V; Meszaros K
Value Health Reg Issues; 2019 Sep; 19():34-44. PubMed ID: 30776766
[TBL] [Abstract][Full Text] [Related]
7. Pneumococcal conjugate vaccines for preventing acute otitis media in children.
Fortanier AC; Venekamp RP; Boonacker CW; Hak E; Schilder AG; Sanders EA; Damoiseaux RA
Cochrane Database Syst Rev; 2019 May; 5(5):CD001480. PubMed ID: 31135969
[TBL] [Abstract][Full Text] [Related]
8. A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand.
Varghese L; Talbot L; Govender A; Zhang XH; Mungall BA
Appl Health Econ Health Policy; 2018 Jun; 16(3):331-345. PubMed ID: 29633160
[TBL] [Abstract][Full Text] [Related]
9. 10-Valent pneumococcal non-typeable
Oguoma VM; Wilson N; Mulholland K; Santosham M; Torzillo P; McIntyre P; Smith-Vaughan H; Balloch A; Chatfield M; Lehmann D; Binks MJ; Chang A; Carapetis J; Krause V; Andrews R; Snelling T; Licciardi P; Morris P; Leach AJ
BMJ Open; 2020 May; 10(5):e033511. PubMed ID: 32448790
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children.
Mungall BA; Hoet B; Nieto Guevara J; Soumahoro L
Expert Rev Vaccines; 2022 Feb; 21(2):201-214. PubMed ID: 34882050
[TBL] [Abstract][Full Text] [Related]
11. Can two different pneumococcal conjugate vaccines be used to complete the infant vaccination series? A randomized trial exploring interchangeability of the 13-valent pneumococcal conjugate vaccine and the pneumococcal non-typeable
de Los Santos AM; Rodríguez-Weber MA; Sánchez-Márquez P; Traskine M; Carreño-Manjarrez R; Cervantes-Apolinar MY; Strezova A; Ruiz-Guiñazú J; Ortega-Barria E; Borys D
Expert Rev Vaccines; 2020 Nov; 19(11):995-1010. PubMed ID: 33297773
[No Abstract] [Full Text] [Related]
12. Pneumococcal conjugate vaccines for preventing acute otitis media in children.
de Sévaux JL; Venekamp RP; Lutje V; Hak E; Schilder AG; Sanders EA; Damoiseaux RA
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD001480. PubMed ID: 33231293
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model.
Delgleize E; Leeuwenkamp O; Theodorou E; Van de Velde N
BMJ Open; 2016 Nov; 6(11):e010776. PubMed ID: 27903558
[TBL] [Abstract][Full Text] [Related]
14. Ten years of experience with the pneumococcal non-typeable
Lecrenier N; Marijam A; Olbrecht J; Soumahoro L; Nieto Guevara J; Mungall B
Expert Rev Vaccines; 2020 Mar; 19(3):247-265. PubMed ID: 32195602
[No Abstract] [Full Text] [Related]
15. Interchangeability between pneumococcal conjugate vaccines for pediatric use: a systematic literature review.
Nieto Guevara J; Borys D; DeAntonio R; Guzman-Holst A; Hoet B
Expert Rev Vaccines; 2020 Nov; 19(11):1011-1022. PubMed ID: 31751159
[No Abstract] [Full Text] [Related]
16. Nasopharyngeal carriage of otitis media pathogens in infants receiving 10-valent non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10), 13-valent pneumococcal conjugate vaccine (PCV13) or a mixed primary schedule of both vaccines: A randomised controlled trial.
Beissbarth J; Wilson N; Arrowsmith B; Binks MJ; Oguoma VM; Lawrence K; Llewellyn A; Mulholland EK; Santosham M; Morris PS; Smith-Vaughan HC; Cheng AC; Leach AJ
Vaccine; 2021 Apr; 39(16):2264-2273. PubMed ID: 33766422
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study.
Iwata S; Kawamura N; Kuroki H; Tokoeda Y; Miyazu M; Iwai A; Oishi T; Sato T; Suyama A; François N; Shafi F; Ruiz-Guiñazú J; Borys D
Hum Vaccin Immunother; 2015; 11(4):826-37. PubMed ID: 25830489
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea.
Zhang XH; Leeuwenkamp O; Oh KB; Lee YE; Kim CM
Hum Vaccin Immunother; 2018 Jan; 14(1):85-94. PubMed ID: 29115905
[TBL] [Abstract][Full Text] [Related]
19. Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model.
De Wals P; Black S; Borrow R; Pearce D
Clin Ther; 2009 Oct; 31(10):2152-69. PubMed ID: 19922887
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable
Lu CY; Chung CH; Huang LM; Kruger E; Tan SC; Zhang XH; Chiu NC
Cost Eff Resour Alloc; 2020; 18():30. PubMed ID: 32874139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
